Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING OF CATEGORY I INNOVATIVE DRUG TQB2450 INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT OF SMALL CELL LUNG CANCER ACCEPTE2023.01.13
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT WITH BOAN BIOTECH2023.01.10
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 20222023.01.03
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT2023.01.03
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE PROMOTION AGREEMENT2022.12.29
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA FOR INJECTION2022.12.09
-
VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INNOVATIVE MEDICINE “TCC1727” FILED WITH AND ACCEPTED BY FDA2022.12.09
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20222022.12.01